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fraction (HFpEF) and angina pectoris (AP).Background AP is a predictor of adverse events in patients with heart failure with reduced EF. The implications of AP in HFpEF
are unknown.Methods We analyzed HFpEF patients (EF 50%) who underwent coronary angiography at Duke University Medical
Center from 2000 through 2010 with and without AP in the previous 6 weeks. Time to ﬁrst event was examined
using Kaplan-Meier methods for the primary endpoint of death/myocardial infarction (MI)/revascularization/
stroke (i.e., major adverse cardiac events [MACE]) and secondary endpoints of death/MI/revascularization,
death/MI/stroke, death/MI, death, and cardiovascular death/cardiovascular hospitalization.Results In the Duke Databank, 3,517 patients met criteria for inclusion and 1,402 (40%) had AP. Those with AP were
older with more comorbidities and prior revascularization compared with non-AP patients. AP patients more often
received beta-blockers, angiotensin-converting enzyme inhibitors, nitrates, and statins (all p < 0.05). In unadjusted
analysis, AP patients had increased MACE and death/MI/revascularization (both p < 0.001), lower rates of death
and death/MI (both p < 0.05), and similar rates of death/MI/stroke and cardiovascular death/cardiovascular
hospitalization (both p > 0.1). After multivariable adjustment, those with AP remained at increased risk for
MACE (hazard ratio [HR]: 1.30, 95% conﬁdence interval [CI]: 1.17 to 1.45) and death/MI/revascularization
(HR: 1.29, 95% CI: 1.15 to 1.43), but they were at similar risk for other endpoints (p > 0.06).Conclusions AP in HFpEF patients with a history of coronary artery disease is common despite medical therapy and is
independently associated with increased MACE due to revascularization with similar risk of death, MI, and
hospitalization. (J Am Coll Cardiol 2014;63:251–8) ª 2014 by the American College of Cardiology FoundationAngina pectoris (AP) is the symptomatic condition related
to ischemia and has different prognostic implications in
various patient populations (1). We have previously shown
that the presence of AP in patients with heart failure (HF)
with reduced ejection fraction (EF) is common despite
medical therapy and previous revascularization, and is
associated with increased cardiovascular death or rehospi-
talization (2). Heart failure with preserved ejection fraction
(HFpEF) accounts for upward of 50% of all patients with
HF (3), and the evidence for therapies to reduce adverse, Duke University Medical Center, Durham,
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3; revised manuscript received September 22,events in this population is limited (4). The implications of
AP in HFpEF are not well deﬁned because these patients
have generally been excluded from AP studies (5). We
compared the clinical characteristics and the outcomes
of patients with and without AP in a cohort of HFpEF
patients.
Methods
Patient data were obtained from the Duke Databank for
Cardiovascular Disease (DDCD), an ongoing databank of
all patients undergoing diagnostic cardiac catheterization at
Duke University Medical Center. Patients were included
in the study population if they underwent coronary angi-
ography from January 2000 through December 2010, and
if they had HFpEF and a history of 50% stenosis in at
least 1 epicardial coronary vessel (only those patients with
a history of signiﬁcant coronary artery disease receive
DDCD follow-up). Coronary stenoses were graded by visual
consensus of at least 2 experienced observers. Patients were
Abbreviations
and Acronyms
AP = angina pectoris
CI = conﬁdence interval
DDCD = Duke Databank for
Cardiovascular Disease
EF = ejection fraction
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
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KM = Kaplan-Meier
MACE = major adverse
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MI = myocardial infarction
NYHA = New York Heart
Association
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252deﬁned as having HFpEF if they
had New York Heart Association
(NYHA) functional class II to
IV symptoms in the 2 weeks
before index catheterization and
EF 50% (6). Patients were ex-
cluded from analysis if they had
EF <50%, unknown EF, un-
known NYHA functional class,
primary valvular heart disease
(deﬁned as moderate or severe
aortic or mitral insufﬁciency, or
severe stenosis of any heart valve),
congenital heart disease, acquired
immunodeﬁciency syndrome, or
metastatic cancer.
Data from the index catheter-
ization were prospectively col-
lected as part of routine patient
care. Baseline clinical variablesfor each patient were stored in the DDCD using methods
previously described (7). Follow-up was obtained through
self-administered questionnaires, with telephone follow-up
to nonresponders. Patients not contacted through this
mechanism had vital status determined through a search of
the National Death Index (8).
AP classiﬁcation was based on physician-obtained patient
history just before cardiac catheterization and was deﬁned as
chest pain within the previous 6 weeks. Because many
groups (e.g., women, elderly patients) present with atypical
angina (9,10), we did not want to bias our results by using
a classic angina deﬁnition alone. Given the prognostic value
of angina characteristics, the severity, frequency, and pattern
of occurrence were recorded at baseline. Revascularization
was deﬁned as treatment with percutaneous coronary
intervention or coronary artery bypass graft. Death,
myocardial infarction (MI), stroke, and cardiovascular
rehospitalization were determined using methods previously
described (7).
Statistical analysis. Baseline characteristics are described
with medians and interquartile ranges (IQRs) for continuous
variables and percentages for discrete variables in HFpEF
patients with versus without AP. These characteristics
were compared using the Wilcoxon rank sum test for
continuous variables and chi-square tests for categorical
variables unless otherwise noted. The primary endpoint
was death/MI/revascularization/stroke (i.e., major adverse
cardiac events [MACE]) and secondary endpoints were
death/MI/revascularization, death/MI/stroke, death/MI,
death, and cardiovascular death/cardiovascular hospitaliza-
tion. Multivariable Cox proportional hazards regression
analysis was used to adjust for baseline differences between
groups. A comprehensive set of covariates was used for the
adjustment analysis (see Table 3 footnote) based on clinical
relevance and data from a previous investigation (2). With
the large number of events in each analysis, there was nooverﬁtting problem with adjustment variables. Adjusted
time-to-event results were generated for the endpoints, and
comparisons were made using the log-rank test. A p value
of <0.05 was used to indicate statistical signiﬁcance for all
comparisons. Statistical analyses were performed by Duke
Clinical Research Institute (Durham, North Carolina) using
SAS (version 9.2, SAS Institute, Cary, North Carolina).
The protocol was approved by the institutional review board
at Duke University, and all patients voluntarily provided
written informed consent.
Results
A total of 3,517 patients met the criteria for the study
(Fig. 1), and 1,402 (40%) had AP. In the AP cohort, 48%
had typical angina and 49% had atypical angina in the
previous 6 weeks. AP was described as stable, progressing,
or unstable in 24%, 47%, and 27% of patients in the
preceding 6 weeks, respectively. Using a modiﬁcation of
the Canadian Cardiovascular Society angina grade (11), the
percentage of AP patients with Canadian Cardiovascular
Society classes I (no symptoms with ordinary activity),
II (symptoms with moderate exertion), III (symptoms
with ordinary exertion), IV (symptoms with any exertion
or at rest), and symptoms unrelated to exertion were
0.2%, 13.3%, 15.0%, 41.5%, and 30.1%, respectively. The
median frequency per week of chest pain episodes was 4
(IQR: 3 to 7).
Baseline characteristics for the AP and non-AP groups
are provided in Table 1. As expected, a number of baseline
characteristics differed signiﬁcantly between the cohorts,
with AP patients tending to be older and more likely to
have a prior history of hypertension, diabetes, hyperlipid-
emia, vascular disease, smoking, and coronary revascular-
ization. Notably, those with AP tended to have less severe
NYHA functional class symptoms and were less likely to
have rales or an S3 gallop. Systolic blood pressure was
signiﬁcantly higher in the AP group. The basic laboratory
parameters were similar between the 2 groups even though
there were statistically signiﬁcant differences in several of
the laboratory parameters due to the large sample size. AP
patients more often received beta-blockers, angiotensin-
converting enzyme inhibitors, nitrates, and statins but
were less likely to receive diuretics as compared with non-
AP patients. In this HFpEF population, both groups had
high baseline use of beta-blockers and angiotensin-
converting enzyme inhibitors, but modest use of calcium
channel blockers, nitrates, and hydralazine. In the AP
group, 77% of patients received a beta-blocker, calcium
channel blocker, or nitrate at baseline compared with 68%
in the non-AP group.
The median follow-up time for all patients was 4.0 years
(IQR: 1.6 to 7.6 years). Five-year unadjusted Kaplan-Meier
(KM) survival for the study population was 66.3%. AP
patients were observed to have a signiﬁcantly increased event
rate for the primary endpoint of MACE, as well as death/
Figure 1 Patients Included in This Analysis
AIDS ¼ acquired immunodeﬁciency syndrome; EF ¼ ejection fraction.
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253MI/revascularization (Table 2). Of note, many of the events
for the MACE composite occurred early following the index
catheterization (30-day and 6-month unadjusted KM event
rates of 32.4% and 37.4% for the AP group, respectively). By
contrast, the event rates were lower in the AP patients
for the endpoints of death/MI and death compared with
those in patients without AP (both p < 0.05). There were
no signiﬁcant differences between the event rates in those
with and without AP for the endpoints of death/MI/
stroke, and cardiovascular death/cardiovascular hospitaliza-
tion (Table 2).
Following risk adjustment, AP was associated with
a signiﬁcantly higher risk of MACE and death/MI/revas-
cularization than was no AP (both p < 0.0001) (Table 3).
AP was an independent predictor of MACE (hazard ratio
[HR]: 1.30, 95% conﬁdence interval [CI]: 1.17 to 1.45)
(Table 3). Patients with and without AP had similar risk
for death/MI/stroke, death/MI, death, and cardiovascular
death/cardiovascular hospitalization (all p > 0.06) (Table 3).
Results for the composite endpoint of all-cause death/
hospitalization in those with AP (adjusted HR: 0.91, 95%
CI: 0.83 to 1.00; p ¼ 0.056) were similar to the results for
cardiovascular death/cardiovascular hospitalization. The
adjusted time-to-event plots in patients with versus without
AP are presented in Figures 2 to 5.Discussion
There were several important ﬁndings from this study. First,
AP was common in this HFpEF cohort despite medical
therapy and previous revascularization. Most of these
patients had angina that was progressive or unstable in the
preceding weeks, with >50% experiencing Canadian
Cardiovascular Society class III or IV symptoms. Second,
HFpEF patients with AP had more comorbidities and more
previous revascularization procedures than did non-AP
patients. After multivariable risk adjustment, those with
recent AP were at signiﬁcantly increased risk for MACE.
However, AP was not associated with increased risk for
death/MI/stroke, death/MI, death, or cardiovascular death/
hospitalization following adjustment for baseline charac-
teristics. Thus, AP was an independent predictor of
MACE driven by increased revascularization, but it was not
associated with increased risk of death, MI, stroke, or
rehospitalization.
Although the prevalence of AP in HFpEF patients is
lower than in patients with HF with reduced EF (2,6),
a signiﬁcant percentage of HFpEF patients have AP. We
found that 40% of HFpEF patients had AP despite previous
revascularization (25% with coronary artery bypass grafting
and 23% with percutaneous coronary intervention) and high
Table 1 Baseline Patient Characteristics
Variable
Angina Pectoris
(Past 6 Weeks)
p Value
No
(n ¼ 2,115)
Yes
(n ¼ 1,402)
Age, yrs 62 (51, 71) 65 (55, 73) <0.001
Men 44 48 0.062
Race <0.001
White 69 69
Black 28 26
Hypertension 58 78 <0.001
Diabetes mellitus 29 41 <0.001
Prior myocardial infarction 13 26 <0.001
Hyperlipidemia* 37 66 <0.001
3-vessel coronary disease 13 24 <0.001
Ejection fraction, % 60 (55–60) 60 (55–67) <0.001
New York Heart Association functional classes III, IV 75 60 <0.001
Cerebrovascular disease 9 15 <0.001
Peripheral vascular disease 5 13 <0.001
Previous smoking 36 48 <0.001
Previous percutaneous coronary intervention 6 23 <0.001
Previous coronary bypass 12 25 <0.001
Indications for index catheterization
Shortness of breath 53 35 <0.001
Heart failure 39 30 <0.001
Charlson index <0.001
0 49 38
1 31 33
2 20 29
Body mass index, kg/m2 28 (24–35) 31 (26–36) <0.001
Heart rate, beats/min 78 (68–90) 71 (62–83) <0.001
Systolic blood pressure, mm Hg 135 (119–153) 147 (130–166) <0.001y
Rales 20 14 <0.001
S3 gallop 9 4 <0.001
LVEDP, mm Hgz 16 (11–22) 16 (12–22) 0.37
Serum sodium, mmol/l 139 (137–141) 140 (138–141) 0.003
Blood urea nitrogen, mg/dl 20 (14–30) 18 (13–25) <0.001
Serum creatinine, mg/dl 1.1 (0.9–1.5) 1.1 (0.9–1.4) 0.016
Hemoglobin, g/dl 12.6 (11.0–14.0) 12.9 (11.5–14.1) <0.001
Beta-blocker use 60 72 <0.001
ACE inhibitor/angiotensin receptor blocker 54 64 <0.001
Hydralazine use 11 7 <0.001
Nitrates use 12 15 0.006
Calcium channel blocker use 42 45 0.12
Ranolazine usex 0.6 0.4 0.29
Aspirin use 58 77 <0.001
Clopidogrel use 18 37 <0.001
Statin use 39 60 <0.001
Diuretic use 71 66 <0.001
Values are median (interquartile range) or %. *Hyperlipidemia ¼ cholesterol >200 mg/dl, low-density lipoprotein >130 mg/dl, high-density lipo-
protein <30 mg/dl, or triglycerides >150 mg/dl. yHere, the p value is calculated using a t test. zLVEDP was available for 2,280 patients (65%) of the
overall cohort: 1,104 patients (52%) in the non-AP group; 1,176 patients (84%) in the AP group. xRanolazine was approved by the U.S. Food and Drug
Administration in 2006.
ACE ¼ angiotensin-converting enzyme; AP ¼ angina pectoris; LVEDP ¼ left ventricular end-diastolic pressure.
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254usage of beta-blockers. The modest usage of calcium channel
blockers, nitrates, and ranolazine in this cohort suggests that
there is room for signiﬁcant improvement in the use of
medical therapies to reduce AP in these patients (1). These
ﬁndings are particularly relevant in the context of the paucityof treatments for HFpEF patients. Potentially, by targeting
angina symptoms with presently available medical therapies,
the morbidity related to repeat revascularizations in HFpEF
patients could be reduced. Despite the relative contraindi-
cation to calcium channel blockers in HF with reduced EF
Table 2 5- and 10-Year Unadjusted Event Rates for Those With and Without AP
Endpoint
5 Years 10 Years
p Value*
Angina Pectoris Angina Pectoris
No Yes No Yes
Death/myocardial infarction/revascularization/stroke
Events (ﬁrst) for composite 848 797 948 910
Death 528 299 608 382
Myocardial infarction 19 15 22 16
Revascularization 222 425 230 436
Stroke 79 58 88 76
KM rate for composite (95% CI) 47.0 (44.6–49.5) 59.2 (56.6–61.9) 61.7 (58.5–64.9) 73.6 (70.7–76.4) <0.001
Death/myocardial infarction/revascularization
Events (ﬁrst) for composite 803 768 908 876
Death 525 243 614 336
Myocardial infarction 30 23 37 27
Revascularization 248 502 257 513
KM rate for composite (95% CI) 44.5 (42.1–47.0) 57.1 (54.4–59.8) 59.8 (56.5–63.1) 71.2 (68.2–74.1) <0.001
Death/myocardial infarction/stroke
Events (ﬁrst) for composite 716 502 844 693
Death 573 325 680 468
Myocardial infarction 42 53 49 73
Stroke 101 124 115 152
KM rate for composite (95% CI) 40.9 (38.5–43.3) 38.4 (35.7–41.1) 58.2 (54.9–61.4) 60.1 (57.0–63.2) 0.33
Death/myocardial infarction
Events (ﬁrst) for composite 657 428 790 621
Death 612 369 735 536
Myocardial infarction 45 59 55 85
KM rate for composite (95% CI) 37.7 (35.3–40.1) 32.9 (30.4–35.5) 55.4 (52.2–58.8) 55.3 (52.1–58.6) 0.019
Death
Events 632 391 767 583
KM rate (95% CI) 36.2 (33.9–38.5) 30.1 (27.6–32.7) 54.2 (50.9–57.5) 52.7 (49.5–56.0) 0.002
Cardiovascular death/cardiovascular hospitalization
Events (ﬁrst) for composite 1,115 787 1,179 881
Cardiovascular death 199 82 212 105
Cardiovascular hospitalization 916 705 967 776
KM rate for composite (95% CI) 63.7 (61.2–66.2) 61.1 (58.4–63.9) 75.0 (71.8–78.1) 75.9 (72.7–78.9) 0.12
Values are number of instances (n) unless otherwise indicated. *The p value represents the result of a log-rank test between those with angina pectoris and those without over the entire follow-up for the
composite endpoints.
AP ¼ angina pectoris; CI ¼ conﬁdence interval; KM ¼ Kaplan-Meier.
Table 3 AP as a Predictor of Outcome on Adjusted Analysis
Endpoint
Adjusted HR*
(95% CI) p Value
Death/myocardial infarction/
revascularization/stroke
1.30 (1.17–1.45) <0.0001
Death/myocardial infarction/
revascularization
1.29 (1.15–1.43) <0.0001
Death/myocardial infarction/stroke 0.99 (0.87–1.11) 0.81
Death/myocardial infarction 0.93 (0.82–1.06) 0.27
Death 0.94 (0.82–1.06) 0.30
Cardiovascular death/cardiovascular
hospitalization
0.95 (0.85–1.05) 0.32
*Adjusted for age; ejection fraction; sex; race; hypertension; diabetes; previous myocardial infarc-
tion; hyperlipidemia; New York Heart Association functional class; cerebrovascular disease;
peripheral vascular disease; previous smoking history; previous percutaneous coronary interven-
tion; previous coronary artery bypass graft; ventricular gallop; Charlson index; body mass index;
heart rate; systolic blood pressure; use of beta-blocker, ACE inhibitor or angiotensin receptor
blocker, hydralazine, nitrates, calcium channel blocker, aspirin, clopidogrel, statin, or diuretic;
serum creatinine; serum sodium; blood urea nitrogen; and hemoglobin.
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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255patients (12), further investigation is needed to deﬁne the
use of calcium channel blockers as antianginals in HFpEF
patients.
The AP patients in this cohort had a distinct phenotype
from those without AP. Speciﬁcally, the AP patients were
less likely to have rales, an S3 gallop, or baseline diuretic use,
and they tended to have a lower NYHA functional class.
Thus, these patients may have had more prominent anginal
symptoms rather than volume overload with fatigue and
dyspnea, which are used to characterize NYHA functional
class.
The death/MI/revascularization/stroke event curves for
the cohorts began to diverge early (i.e., within the ﬁrst
6 months) with a persistent effect up to 10 years after the
index catheterization. After adjusting for baseline comor-
bidities and medication use, AP remained a strong inde-
pendent predictor of MACE. It was found that AP was
associated with a 30% increased risk of long-term death/MI/
Figure 4 Adjusted Time-to-Event Plot for Death
Adjusted time-to-event plot for death in heart failure with preserved ejection
fraction patients with versus without angina pectoris. Adjusted for the variables
listed in the Table 3 footnote.
Figure 2 Adjusted Time-to-Event Plot for MACE
Adjusted time-to-event plot for death, myocardial infarction, revascularization, or
stroke in heart failure with preserved ejection fraction patients with versus without
angina pectoris. Adjusted for the variables listed in the Table 3 footnote. MACE ¼
major adverse cardiac events.
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256revascularization/stroke. These ﬁndings, along with the lack
of association between AP and other endpoints on adjusted
analysis, suggest that the implications for AP are most
strongly correlated with increased revascularization. These
results support previous data that revascularization may be
performed to relieve anginal symptoms, but it may not
improve prognosis unless the patient demonstrates other
high-risk features (1).
These results have important clinical applications, given
the procedural costs and quality of life implications for
revascularization procedures. Previous studies have alsoFigure 3 Adjusted Time-to-Event Plot for Death or MI
Adjusted time-to-event plot for death or myocardial infarction (MI) in heart failure
with preserved ejection fraction patients with versus without angina pectoris.
Adjusted for the variables listed in the Table 3 footnote.suggested that HFpEF patients with coronary artery disease
who present with pulmonary edema tend to have recurrence
of pulmonary edema despite revascularization (13). Thus,
a reappraisal of the utility of revascularization in HFpEF
patients may be warranted, given potential limitations in
preventing HF decompensation. Future studies will need to
explore whether improved management of AP may reduce
revascularization rates.
Our ﬁndings that AP did not portend increased death or
hospitalization following risk adjustment is concordant withFigure 5
Adjusted Time-to-Event Plot for Cardiovascular
Death or Cardiovascular Hospitalization
Adjusted time-to-event plot for cardiovascular death or cardiovascular
hospitalization in heart failure with preserved ejection fraction patients with
versus without angina pectoris. Adjusted for the variables listed in the Table 3
footnote.
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257previous studies of stable AP in the general (e.g., non-HF)
population. Follow-up of the APSIS (Angina Prognosis
Study in Stockholm) demonstrated that patients with stable
AP had similar all-cause mortality when compared with
patients without AP over a median follow-up of 9 years (14).
We have previously shown that AP in the ischemic
cardiomyopathy population with reduced EF was not asso-
ciated with increased long-term death, death/MI, or death/
all-cause hospitalization (2). The present study extends these
results into the HFpEF population.
The observation that AP was associated with reduced
death and death/MI on unadjusted analysis was unexpected.
Potential reasons for reduced mortality associated with
angina include increased use of prevention therapies (e.g.,
aspirin, statins), heightened physician follow-up, “ischemic
pre-conditioning” protecting against subsequent adverse
outcomes (15,16), and statistical chance. Interestingly, the
between-group difference in outcomes narrowed over time.
Our previous study in the reduced EF population demon-
strated a trend toward reduced mortality associated with AP
on unadjusted analysis (2). Similar to the present results, the
association between AP and death in reduced EF patients
was further attenuated with risk adjustment. Thus, these
data present consistent evidence that AP is not associated
with mortality across the spectrum of HF patients when
baseline characteristics are accounted for.
Study limitations. The DDCD captures a subset of cardiac
patients undergoing cardiac catheterization, which limits
the population studied and may not reﬂect event rates in
a broader population. For instance, the requirement to
undergo cardiac catheterization likely reduced the age of the
patients in the study cohort compared with other HFpEF
datasets. On the other hand, the robust representation of
both women and minorities in the DDCD provides
important insights into patient characteristics and outcomes
in frequently under-represented patient groups. A limitation
related to this dataset is that only those patients with a history
of signiﬁcant coronary artery disease receive DDCD follow-
up. Further empiric testing is required to explore outcomes in
HFpEF patients without epicardial coronary disease, because
underlying signiﬁcant coronary artery disease likely inﬂu-
enced subsequent revascularization considerations. Given
this study’s long accrual time, the subjective AP classiﬁcation
was recorded by many investigators such that there was
inherent variability in the databank. This is a recognized
limitation of the databank, but it also represents the reality of
clinical practice in which clinicians may categorize subjective
symptoms differently. It is also possible that patients in both
the AP and non-AP groups would be weighted toward those
with a higher index of suspicion for intervenable coronary
artery disease. Future studies should explore whether the
degree of ischemia confounds the association between AP
and outcomes because chest pain in HFpEF patients does
not always represent underlying myocardial ischemia. Our
use of AP classiﬁcation at a single time point (index cathe-
terization) is another potential limitation because we did notinvestigate persistent AP or the relation of a subsequent
revascularization to AP. Given the multiple analyses con-
ducted in the present study, these results should be viewed as
exploratory, given the increased likelihood of a type I error.
Our study provides the foundation for future studies of AP
in HFpEF in an attempt to improve patients’ symptoms
and reduce revascularization rates.
Conclusions
AP in HFpEF patients with a history of coronary artery
disease is common despite medical therapy and previous
revascularization, and it is independently associated with
increased MACE due to revascularization, with similar risk
of death, MI, stroke, and hospitalization. Given the paucity
of treatments for HFpEF patients, these data provide the
foundation for pharmacological studies targeting anginal
symptoms to reduce the morbidity associated with repeat
revascularizations. Future prospective studies of angina in
HFpEF patients are warranted.
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